AVEO Pharmaceuticals Inc

AVEO Pharmaceuticals — Investor Presentation (September 2019)

31 slides from AVEO Pharmaceuticals's investor presentation, Sep 10, 2019

  1. Slide 1: AVEO Overview September 2019

    AVEO Overview September 2019 Exhibit 99.2

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained

  3. Slide 3: AVEO Oncology: Strategy for Value Creation

    AVEO Oncology: Strategy for Value Creation Value Enhancing Partnerships Deep Pipeline Addressing Significant Unmet Needs Multiple oncology and non-oncology pipeline opportunities FOTIVDA™ (tivozanib) – IO Combinations (RCC, HCC, other) Highly specific VEGFR TKI has potential to enable unique tolerab

  4. Slide 4: Pipeline: Multiple Potential Opportunities for Value Creation

    Clinical Preclinical Phase 1 Phase 2 Phase 3 Regulatory Filing Marketed Partner Tivozanib (RCC) VEGFR 123 TKI Tivozanib (HCC) VEGFR 123 TKI Ficlatuzumab HGF MAb AV-203 (CAN017) ERBB3 MAb Multiple Potential Opportunities for Value Creation TIVO-1 (Phase 3 Registration Study in 1st Line RCC) TIVO-3 (P

  5. Slide 5: Financial Highlights

    Financial Highlights Cash on hand to fund planned operations into 3Q 2021* $40.2M in cash, cash equivalents, and marketable securities as of 2Q 2019 $25.0M upfront payment from Kyowa Kirin due in 3Q 2019 Kyowa Kirin buy back of tivozanib non-oncology rights: $25M upfront payment Waiver of the $18M p

  6. Slide 6: FOTIVDA (tivozanib) TIVO-3 Pivotal Phase 3 Study

    FOTIVDA® (tivozanib) TIVO-3 Pivotal Phase 3 Study

  7. Slide 7: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor

    Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1 Nakamura K et al. Cancer Res 2006;66:9134–9142. 2 Eskens FA et al. Clin Cancer Res 2011;17:71

  8. Slide 8: TIVO-3: Study Design

    TIVO-3: Study Design N = 350 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI Stratified by prior regimen (TKI-TKI; TKI-PD1; TKI-Other) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and Tolerability for ITT 60% 3rd line patients, 4

  9. Slide 9: Primary Endpoint: Progression-Free Survival per IRC (ITT)

    Primary Endpoint: Progression-Free Survival per IRC (ITT)* Median PFS, mo (95% CI) Tivozanib 5.6 (5.3, 7.3) Sorafenib 3.9 (3.7, 5.6) HR, 0.73 (95% CI: 0.56, 0.94) P=0.0165 2yr PFS 18% 5% 28% 1yr PFS 11% 44% improvement in median PFS 27% risk reduction for progression or death *Final analysis, as of

  10. Slide 10: IO Subgroup Progression-Free Survival per IRC

    IO Subgroup Progression-Free Survival per IRC (26% of ITT)* Median PFS, mo (95% CI) Tivozanib 7.3 (5.3, 11.1) Sorafenib 5.1 (3.6, 7.4) HR, 0.55 (95% CI: 0.32, 0.94) P=0.028 35% 1yr PFS 4% 2yr PFS 25% 43% improvement in median PFS 45% risk reduction for progression or death *Final analysis, as of Oct

  11. Slide 11: Secondary Endpoint – ORR

    Secondary Endpoint – ORR* Final Analysis - Superior Overall Response Rate and Durability Statistically significant benefit in ORR, p=0.02 Durable responses with tivozanib: 55% remaining in response past 2 years Median DoR: tivozanib not reached vs sorafenib 5.7 months *Final analysis, as of Oct 4, 2

  12. Slide 12: Treatment-Related Adverse Events

    Treatment-Related Adverse Events* (≥20% frequency in either arm) Tivozanib (N=173)^ Sorafenib (N=170)^ Preferred Term All Grades % Grade 3/4 % All Grades % Grade 3/4 % Treatment Related AEs 84 44 94 55 Hypertension 36 20 25 14 Diarrhea 33 2 50 9 Fatigue 29 4 19 5 Decreased Appetite 26 4 21 2 Dysphon

  13. Slide 13: Tolerability Results

    Tivozanib (N=173)^ Sorafenib (N=170)^ Mean Number of Cycles Initiated 10.3 6.3 AEs Leading to Dose Reductions (%) 24 38 AEs Leading to Dose Interruption (%) 48 63 Treatment Related SAEs (%) 11 10 Treatment Related Deaths (%) 0 0 Deaths within 30 days of Tx (N) 15 12 Exposure Adj Deaths per Month of

  14. Slide 14: Secondary Endpoint – Overall Survival

    Secondary Endpoint – Overall Survival Initial OS Analysis (Oct 4, 2018): HR* >1.00 Analysis based on 183 OS events Prespecified OS Analysis update (Aug 15, 2019): HR*=0.99 Analysis based on 227 OS events 95% CI: 0.76-1.29; p=0.95 44 additional events since Oct 4, 2018 data cut 16 tivozanib events an

  15. Slide 15: TIVO-3 Conclusions

    TIVO-3 Conclusions Tivozanib significantly improves PFS and ORR compared to sorafenib in patients with treatment-refractory advanced RCC Tivozanib was superior in patients previously treated with checkpoint inhibitors as well as two VEGFR-TKIs Responses with tivozanib were more durable than sorafeni

  16. Slide 16: PD-1 Combination Opportunities

    PD-1 Combination Opportunities

  17. Slide 17: Tivozanib Properties May Provide Advantages in Combination with IO Therapy

    Tivozanib Properties May Provide Advantages in Combination with IO Therapy Nakamura K et al. Cancer Res 2006;66:9134–9142. Pawlowski N et al. AACR 2013. Poster 3971. Hammers, Emerging VEGF-I/O Combinations, ASCO 2017

  18. Slide 18: Demonstrated Favorable Safety Results

    Demonstrated Favorable Safety Results 60% of patients experienced treatment related grade 3/4 adverse event Excluding uncomplicated hypertension, only 44% of patients experienced grade 3/4 adverse event Minimal off-target AEs observed, likely due to high specificity of tivozanib Barthelemy et al. ES

  19. Slide 19: Encouraging Preliminary Efficacy Results

    Encouraging Preliminary Efficacy Results 56% ORR and 96% DCR 72% had tumor shrinkage ≥25% as of August 2018 4% (1/25) of patients had a complete response 52% (13/25) of pts remain on therapy Results suggest additive or synergistic efficacy for tivozanib + PD1 Barthelemy et al. ESMO 2018 Updated Resu

  20. Slide 20: Immuno-Oncology Clinical Collaboration with AstraZeneca

    Immuno-Oncology Clinical Collaboration with AstraZeneca Clinical Rationale: Single agent activity demonstrated for tivozanib and durvalumab in HCC2,3. Combination of two agents has potential to show enhanced efficacy and best in class tolerability profile among TKI/IO regimens. Planned phase 1/2 stu

  21. Slide 21: Tivozanib Commercial Opportunity

    Tivozanib Commercial Opportunity

  22. Slide 22: Significant Potential Commercial Opportunity for Tivozanib in the United States

    If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States 1st Line Market (est. 2020) ~$1.6B1 2nd Line Market (est. 2020) ~$700M1 3rd Line+ Market (est. 2020) ~$300M1 Expect opportunity to expand Potential to be first agent indicated for 3rd & 4th line Only pivotal

  23. Slide 23: Potential Relevance of Tivozanib in Refractory RCC

    Potential Relevance of Tivozanib in Refractory RCC Source: AVEO blinded Third-Party US Oncologist Market Research using approximate TIVO-3 PFS and AE profile - Dec 2018 n=100 Treatments with proven efficacy are needed for patients who have failed 2 or more lines of treatment for RCC I prefer using d

  24. Slide 24: FOTIVDA Commercialization in EU and ROW

    First-line treatment for patients with good or intermediate risk Second-line patients following TKIs Launched in Germany, Spain and UK Approved in New Zealand https://www.esmo.org/Guidelines/Genitourinary-Cancers/Renal-Cell-Carcinoma FOTIVDA Commercialization in EU and ROW This Photo by Unknown Auth

  25. Slide 25: Pipeline and Near-Term Milestones

    Pipeline and Near-Term Milestones

  26. Slide 26: Tivozanib

    Tivozanib * Does not include potential PTE up to 5 yr max VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Launched in Europe by EUSA as FOTIVDA in first line RCC in November 2017 TIVO-3 study on-going for potential U.S. registration for RCC IO combination study with OPDIVO® in collaboration with BMS unde

  27. Slide 27: Ficlatuzumab

    Ficlatuzumab * Does not include potential PTE up to 5 yr max HGF Inhibitory Antibody with Optimal Blockade of c-Met AML: Phase 1/2 Trial of ficlatuzumab and cytarabine in refractory AML patients Demonstrated 50% complete response in patients refractory to initial therapy Randomized phase 2 in planni

  28. Slide 28: Anti-ERBB3 Mab with Broad Therapeutic Potential

    Anti-ERBB3 Mab with Broad Therapeutic Potential CANbridge to fund clinical development through Phase 2 POC study Potential additional $40M development and regulatory/$90M commercial milestone Tiered low double-digit royalties for ex-NA rights Planned indication: squamous cell esophageal cancer (IND

  29. Slide 29: First-in-Class, Anti-GDF15 MAb for Cachexia

    First-in-Class, Anti-GDF15 MAb for Cachexia Affects approximately 5 million patients in the US alone; affects up to 80% of advanced cancer patients and is responsible for approximately 30% of all cancer deaths1,2 Pre-clinical development underway to enable planned IND submission in 2020 Composition

  30. Slide 30: AVEO Key Near Term Potential Milestones

    AVEO Key Near Term Potential Milestones Tivozanib (VEGFR 1, 2 and 3 TKI) 2H19 1H20 2H20 TIVO-3 OS Update / Regulatory Discussion DEDUCTIVE HCC Ph 1/2 (Durvalumab + Tivo) Enrollment Start TiNivo RCC (Nivolumab + Tivo) Final PFS Presentation Ficlatuzumab (HGF Inhibitory Antibody) 2H19 1H20 2H20 AML Ra

  31. Slide 31: AVEO Overview September 2019

    AVEO Overview September 2019

AVEO Pharmaceuticals — Investor Presentation (September 2019) on 6ix